Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +11.09%12 Altman Z-Score is 18.97 as of Sep. 18, 2026, which is 31% above its 10-year median of 14.48. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 810 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 89.51% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 14.91 is strong.
Alamar Biosciences has a Altman Z-Score of 18.97, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Alamar Biosciences's Altman Z-Score or its related term are showing as below:
ALMR'
s Altman Z-Score Range Over the Past 10 Years
Min: 14.48 Med: 14.48 Max: 14.91
Current: 14.91
During the past 2 years, Alamar Biosciences's highest Altman Z-Score was 14.91. The lowest was 14.48. And the median was 14.48.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Alamar Biosciences Altman Z-Score Related Terms
Alamar Biosciences Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Altman Z-Score Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Altman Z-Score
0.00
0.00
Alamar Biosciences Quarterly Data
Mar25
Jun25
Mar26
Jun26
Altman Z-Score
0.00
0.00
0.00
0.00
ALMR vs ESTA, NVCR, BFLY: Altman Z-Score Comparison
For the Medical Devices subindustry, Alamar Biosciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Alamar Biosciences's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7761
+
1.4
*
-0.52
+
3.3
*
-0.1235
+
0.6
*
31.5971
+
1.0
*
0.2167
=
18.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Alamar Biosciences (ALMR) has a Altman Z-Score of 18.97 as of Sep. 18, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alamar Biosciences and its competitors. This is 31% above median its historical median of 14.48. Over the past decade, Alamar Biosciences' Altman Z-Score has ranged from 14.48 to 14.91. According to the industry distribution chart, Alamar Biosciences ranks #85 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 10.5%.
Is Alamar Biosciences' Altman Z-Score too high?
Alamar Biosciences' current Altman Z-Score of 18.97 is 31% above median its 10-year median of 14.48. Over the past 10 years, this metric has ranged from a low of 14.48 to a high of 14.91. The Medical Devices & Instruments industry median Altman Z-Score is 3.07. Alamar Biosciences' value of 18.97 is 517.9% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #85 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Altman Z-Score compare to ESTA and NVCR?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #85 out of 810 companies for Altman Z-Score. This places Alamar Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.07. Alamar Biosciences' value of 18.97 is 517.9% above this benchmark. Historically, Alamar Biosciences' own Altman Z-Score has ranged from 14.48 to 14.91 over the past decade. While the company's 10-year median is 14.48 vs. the industry median of 3.07, Alamar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.07, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Altman Z-Score of 18.97 is 517.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Altman Z-Score is 18.97, which is 31% above median its own 10-year median of 14.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Altman Z-Score of 18.97. The current Altman Z-Score is 18.97, which is 31% above median its 10-year median of 14.48 and 517.9% above the Medical Devices & Instruments industry median of 3.07. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Altman Z-Score is 18.97 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score
Get the complete analysis for ALMR
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
